Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
5 shownSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rat...
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...
Frequent Co-Authors
Researcher Info
- h-index
- 5
- Publications
- 5
- Citations
- 12,378
- Institution
- Merck & Co., Inc., Rahway, NJ, USA (United States)
External Links
Impact Metrics
h-index
5
h-index: Number of publications with at least h citations each.